1. Etanercept-induced necrotizing crescentic glomerulonephritis in two patients with rheumatoid arthritis
- Author
-
Kayoko Kaneko, Toshihiro Nanki, Fumitaka Mizoguchi, Tadashi Hosoya, and Nobuyuki Miyasaka
- Subjects
musculoskeletal diseases ,Adult ,medicine.medical_specialty ,Arthritis ,urologic and male genital diseases ,Gastroenterology ,Receptors, Tumor Necrosis Factor ,Etanercept ,Arthritis, Rheumatoid ,Necrosis ,Glomerulonephritis ,Rheumatology ,Internal medicine ,medicine ,Humans ,Renal Insufficiency ,skin and connective tissue diseases ,Hematuria ,Proteinuria ,medicine.diagnostic_test ,business.industry ,Tumor Necrosis Factor-alpha ,Middle Aged ,medicine.disease ,female genital diseases and pregnancy complications ,Rheumatoid arthritis ,Antirheumatic Agents ,Immunoglobulin G ,Immunology ,Prednisolone ,Female ,Renal biopsy ,medicine.symptom ,business ,Nephritis ,medicine.drug - Abstract
We present two patients with rheumatoid arthritis (RA) who developed necrotizing crescentic glomerulonephritis (NCGN) during etanercept therapy. Both patients developed proteinuria and hematuria, and one progressed to renal failure. Renal biopsy revealed NCGN. In both patients, nephritis improved following discontinuation of etanercept and administration of prednisolone. Physicians should be aware of etanercept-induced GN in patients with RA on anti-tumor necrosis factor therapy.
- Published
- 2010